Joshua F Baker1, Joan Marie Von Feldt2, Sogol Mostoufi-Moab2, Woojin Kim2, Elena Taratuta2, Mary B Leonard2. 1. From the Division of Rheumatology, Philadelphia Veteran Affairs (VA) Medical Center; Division of Rheumatology, and Department of Biostatistics and Epidemiology, and Children's Hospital of Philadelphia, Department of Pediatrics, and Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Pediatrics and Medicine, Stanford University, Stanford, California, USA.J.F. Baker, MD, MSCE, Division of Rheumatology, Philadelphia VA Medical Center, and Division of Rheumatology, and Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania; J.M. Von Feldt, MD, MSEd, Division of Rheumatology, Philadelphia VA Medical Center, and Division of Rheumatology, Perelman School of Medicine, University of Pennsylvania; S. Mostoufi-Moab, MD, MSCE, Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania; W. Kim, MD, Department of Radiology, Perelman School of Medicine, University of Pennsylvania; E. Taratuta, MD, Department of Radiology, Perelman School of Medicine, University of Pennsylvania; M.B. Leonard, MD, MSCE, Department of Pediatrics and Medicine, Stanford University. bakerjo@uphs.upenn.edu. 2. From the Division of Rheumatology, Philadelphia Veteran Affairs (VA) Medical Center; Division of Rheumatology, and Department of Biostatistics and Epidemiology, and Children's Hospital of Philadelphia, Department of Pediatrics, and Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Pediatrics and Medicine, Stanford University, Stanford, California, USA.J.F. Baker, MD, MSCE, Division of Rheumatology, Philadelphia VA Medical Center, and Division of Rheumatology, and Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania; J.M. Von Feldt, MD, MSEd, Division of Rheumatology, Philadelphia VA Medical Center, and Division of Rheumatology, Perelman School of Medicine, University of Pennsylvania; S. Mostoufi-Moab, MD, MSCE, Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania; W. Kim, MD, Department of Radiology, Perelman School of Medicine, University of Pennsylvania; E. Taratuta, MD, Department of Radiology, Perelman School of Medicine, University of Pennsylvania; M.B. Leonard, MD, MSCE, Department of Pediatrics and Medicine, Stanford University.
Abstract
OBJECTIVE: Rheumatoid arthritis (RA) is associated with low muscle mass and density. The objective of our study was to evaluate associations between 2 serum biomarkers [insulin-like growth factor 1 (IGF-1) and adiponectin] and skeletal muscle in RA. METHODS: Whole-body dual energy X-ray absorptiometry measures of the appendicular lean mass index (ALMI; kg/m(2)) and total fat mass index (kg/m(2)), as well as the peripheral quantitative computed tomography measures of the lower leg muscle and fat cross-sectional area (CSA; cm(2)) and muscle density (an index of fat infiltration) were obtained from 50 participants with RA, ages 18-70 years. Multivariable linear regression analyses evaluated associations between body composition and levels of adiponectin and IGF-1, adjusted for age, sex, and adiposity. RESULTS: Greater age was associated with higher adiponectin (p = 0.06) and lower IGF-1 (p = 0.004). Eight subjects had IGF-1 levels below the reference range for their age and sex. These subjects had significantly lower ALMI and muscle CSA in multivariable models. Lower IGF-1 levels were associated with greater clinical disease activity and severity, as well as low ALMI, muscle CSA, and muscle density (defined as 1 SD below normative mean). After adjusting for age and sex, greater adiponectin levels were associated with lower BMI (p = 0.02) as well as lower ALMI, and lower muscle CSA, independent of adiposity (p < 0.05). Only greater Health Assessment Questionnaire scores were significantly associated with lower adiponectin levels. CONCLUSION: Low IGF-1 and greater adiponectin levels are associated with lower muscle mass in RA. Lower IGF-1 levels were seen in subjects with greater disease activity and severity.
OBJECTIVE:Rheumatoid arthritis (RA) is associated with low muscle mass and density. The objective of our study was to evaluate associations between 2 serum biomarkers [insulin-like growth factor 1 (IGF-1) and adiponectin] and skeletal muscle in RA. METHODS: Whole-body dual energy X-ray absorptiometry measures of the appendicular lean mass index (ALMI; kg/m(2)) and total fat mass index (kg/m(2)), as well as the peripheral quantitative computed tomography measures of the lower leg muscle and fat cross-sectional area (CSA; cm(2)) and muscle density (an index of fat infiltration) were obtained from 50 participants with RA, ages 18-70 years. Multivariable linear regression analyses evaluated associations between body composition and levels of adiponectin and IGF-1, adjusted for age, sex, and adiposity. RESULTS: Greater age was associated with higher adiponectin (p = 0.06) and lower IGF-1 (p = 0.004). Eight subjects had IGF-1 levels below the reference range for their age and sex. These subjects had significantly lower ALMI and muscle CSA in multivariable models. Lower IGF-1 levels were associated with greater clinical disease activity and severity, as well as low ALMI, muscle CSA, and muscle density (defined as 1 SD below normative mean). After adjusting for age and sex, greater adiponectin levels were associated with lower BMI (p = 0.02) as well as lower ALMI, and lower muscle CSA, independent of adiposity (p < 0.05). Only greater Health Assessment Questionnaire scores were significantly associated with lower adiponectin levels. CONCLUSION: Low IGF-1 and greater adiponectin levels are associated with lower muscle mass in RA. Lower IGF-1 levels were seen in subjects with greater disease activity and severity.
Authors: Joshua F Baker; Matthew Davis; Ruben Alexander; Babette S Zemel; Sogol Mostoufi-Moab; Justine Shults; Michael Sulik; Daniel J Schiferl; Mary B Leonard Journal: Bone Date: 2012-12-11 Impact factor: 4.398
Authors: Joshua F Baker; Jin Long; Sogol Mostoufi-Moab; Michele Denburg; Erik Jorgenson; Prerna Sharma; Babette S Zemel; Elena Taratuta; Said Ibrahim; Mary B Leonard Journal: J Rheumatol Date: 2017-09-15 Impact factor: 4.666
Authors: Joshua F Baker; Anne B Newman; Alka Kanaya; Mary B Leonard; Babette Zemel; Iva Miljkovic; Jin Long; David Weber; Tamara B Harris Journal: J Gerontol A Biol Sci Med Sci Date: 2019-01-16 Impact factor: 6.053
Authors: Joshua F Baker; Patricia Katz; David R Weber; Patrick Gould; Michael D George; Jin Long; Babette S Zemel; Jon T Giles Journal: Arthritis Care Res (Hoboken) Date: 2021-09-24 Impact factor: 4.794
Authors: Joshua F Baker; Sogol Mostoufi-Moab; Jin Long; Elena Taratuta; Mary B Leonard; Babette Zemel Journal: Arthritis Care Res (Hoboken) Date: 2021-03 Impact factor: 4.794
Authors: Klara Komici; Antonio Dello Iacono; Antonio De Luca; Fabio Perrotta; Leonardo Bencivenga; Giuseppe Rengo; Aldo Rocca; Germano Guerra Journal: Front Endocrinol (Lausanne) Date: 2021-04-15 Impact factor: 5.555